Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Wegener's granulomatosis, microscopic polyangiitis, and idiopathic pauci-immune necrotizing crescentic glomerulonephritis (NCGN) are strongly associated with antineutrophil cytoplasmic autoantibodies (ANCAs) directed against either proteinase 3 (anti-PR3) or myeloperoxidase (anti-MPO). This has led some investigators to prefer combining these diseases under the common heading of ANCA-associated vasculitides. However, it is increasingly recognized that there are characteristic differences between patients with anti-PR3 and those with anti-MPO-associated vasculitis. This review focuses on the clinical, histopathologic, and possibly pathophysiologic differences between anti-PR3- and anti-MPO-associated vasculitis. Although there is considerable overlap, the anti-PR3- and anti-MPO-associated vasculitides are each characterized by particular clinical and histopathological findings. Extrarenal organ manifestations and respiratory tract granulomas occur more frequently in patients with anti-PR3 than in those with anti-MPO. Anti-PR3-positive patients with NCGN generally have a more dramatic deterioration of their renal function compared with anti-MPO-positive patients. The term "ANCA-associated vasculitis" is considered as a useful concept in the presence of systemic vasculitis. Likewise, in the presence of vasculitis, the terms "anti-PR3-associated vasculitis" and "anti-MPO-associated vasculitis" are useful concepts.

[1]  R. van Wijk,et al.  In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. , 1999, Clinical and experimental rheumatology.

[2]  E. Mirapeix,et al.  Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Kallenberg,et al.  In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. , 1999, Journal of the American Society of Nephrology : JASN.

[4]  E. Hachulla,et al.  Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. , 1999, The American journal of medicine.

[5]  J. G. Taylor,et al.  Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. , 1999, American journal of clinical pathology.

[6]  P. Chapman,et al.  The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. , 1999, Kidney international.

[7]  C. Kallenberg,et al.  Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. , 1998, Journal of the American Society of Nephrology : JASN.

[8]  C. Franssen,et al.  Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti‐proteinase 3 and anti‐myeloperoxidase autoantibodies , 1998, Journal of internal medicine.

[9]  G. Hoffman,et al.  Antineutrophil cytoplasmic antibodies. , 1998, Bulletin on the rheumatic diseases.

[10]  King,et al.  T lymphocyte responses to anti‐neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA‐associated systemic vasculitis and persist during disease remission , 1998, Clinical and experimental immunology.

[11]  A. Vizjak,et al.  Antineutrophil cytoplasmic autoantibodies in atheroembolic disease. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  P Lesavre,et al.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.

[13]  K. Ho,et al.  Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration. , 1998, Clinical imaging.

[14]  C. Kallenberg,et al.  Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. , 1998, Kidney international.

[15]  C. Michelet,et al.  The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? , 1998, Clinical nephrology.

[16]  C. Lockwood,et al.  Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis , 1997, Clinical and experimental immunology.

[17]  Dominique,et al.  Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. , 1997, Arthritis and rheumatism.

[18]  K. De Groot,et al.  Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). , 1997, Journal of immunological methods.

[19]  J. Tervaert,et al.  Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. , 1997, Seminars in arthritis and rheumatism.

[20]  W. Gross,et al.  High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. , 1997, The American journal of medicine.

[21]  A. Maxwell,et al.  Up‐regulation of the endothelial cell adhesion molecule intercellular adhesion molecule‐1 (ICAM‐1) by autoantibodies in autoimmune vasculitis , 1997, Clinical and experimental immunology.

[22]  B. Persson,et al.  Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? , 1997, Clinical and experimental immunology.

[23]  D. Adu,et al.  Primary systemic vasculitis , 1997, The Lancet.

[24]  A. Devys,et al.  Anti‐native and recombinant myeloperoxidase monoclonals and human autoantibodies , 1997, Clinical and experimental immunology.

[25]  T. Colby ANCA defines the clinical disease manifestations of vasculitis. The "con" side of the issue. , 1996, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[26]  C. Kallenberg,et al.  Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. , 1996, Journal of immunological methods.

[27]  J. T. ter Maaten,et al.  Respiratory failure in ANCA-associated vasculitis. , 1996, Chest.

[28]  A. Mantovani,et al.  Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. , 1996, Arthritis and rheumatism.

[29]  C. Pusey,et al.  C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  C. Pusey,et al.  T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis , 1996, Clinical and experimental immunology.

[31]  A. Schwarting,et al.  Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule‐1 (VCAM‐1) , 1996, Clinical and experimental immunology.

[32]  A. Wiik,et al.  ANCA antigens: Myeloperoxidase , 1996 .

[33]  A. Wiik,et al.  ANCA antigens: Proteinase 3 , 1996 .

[34]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[35]  J. Kramer,et al.  Aphasia, apraxia, and agnosia in the diagnosis of dementia. , 1996, Dementia.

[36]  M. Rastaldi,et al.  Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  J. Feussner,et al.  A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis , 1995, The Lancet.

[38]  I. Bruce,et al.  An audit of ANCA in routine clinical practice. , 1995, Postgraduate medical journal.

[39]  J. Savige,et al.  Epitope mapping of anti‐proteinase 3 and anti‐myeloperoxidase antibodies , 1995, Clinical and experimental immunology.

[40]  S. Eriksson,et al.  The PiZ gene of α1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis , 1995 .

[41]  Y. Sommarin,et al.  Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. , 1995, Experimental nephrology.

[42]  K. Kawasaki,et al.  Significance of myeloperoxidase in rapidly progressive glomerulonephritis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  M. Arnaout,et al.  Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. , 1995, Kidney international.

[44]  J. Savige,et al.  α1‐Antitrypsin deficiency and anti‐proteinase 3 antibodies in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis , 1995, Clinical and experimental immunology.

[45]  C. Pusey,et al.  ANCA and predicting relapse in systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.

[46]  U. Helmchen,et al.  Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[47]  S. Eriksson,et al.  PR3-ANCA-positive vasculitis , 1995 .

[48]  R. Gans,et al.  Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. , 1995, Kidney international.

[49]  C. Kallenberg,et al.  T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG) , 1994, Clinical and experimental immunology.

[50]  P. Limburg,et al.  Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA): a FcγRII‐dependent process , 1994, Clinical and experimental immunology.

[51]  T. Jackson,et al.  Invasive amoebiasis is associated with the development of anti‐neutrophil cytoplasmic antibody , 1994, Clinical and experimental immunology.

[52]  C. Kallenberg,et al.  Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. , 1994, Kidney international.

[53]  X. Bosch,et al.  Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. , 1994, Archives of pathology & laboratory medicine.

[54]  D. Underwood,et al.  Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. , 1994, Journal of immunology.

[55]  C. Kallenberg,et al.  Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. , 1994, Kidney international.

[56]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[57]  C. Kallenberg,et al.  Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.

[58]  R. Williams,et al.  Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. , 1994, Arthritis and rheumatism.

[59]  L. Noel,et al.  Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. , 1994, The Journal of rheumatology.

[60]  R. Falk,et al.  Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. , 1994, Advances in experimental medicine and biology.

[61]  K. Büschenfelde,et al.  Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells , 1993, Clinical and experimental immunology.

[62]  D. Adu,et al.  Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.

[63]  R. Goldschmeding,et al.  Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy , 1993, The Lancet.

[64]  A. Borne,et al.  Relevance of classic anti‐neutrophil cytoplasmic autoantibody (C‐ANCA)‐mediated inhibition of proteinase 3‐α1‐antitrypsin complexation to disease activity in Wegener's granulomatosis , 1993, Clinical and experimental immunology.

[65]  M. V. van Leeuwen,et al.  Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. , 1993, Arthritis and rheumatism.

[66]  H. Peter,et al.  ANCA in diseases other than systemic vasculitis , 1993, Clinical and experimental immunology.

[67]  Jean‐Pierre Martin,et al.  Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. , 1993, Kidney international.

[68]  C. Kallenberg,et al.  Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model , 1993, The Journal of experimental medicine.

[69]  C. Kallenberg,et al.  Serum markers of T cell activation in relapses of Wegener's granulomatosis , 1993, Advances in experimental medicine and biology.

[70]  C. Kallenberg,et al.  Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases , 1993, Hepatology.

[71]  C. Hallahan,et al.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. , 1993, Arthritis and rheumatism.

[72]  D. Chauveau,et al.  Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. , 1993, Clinical nephrology.

[73]  E. Mark,et al.  Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis. , 1993, Human pathology.

[74]  K. Kaneko,et al.  Is p-ANCA in ulcerative colitis directed against β-glucuronidase? , 1993, The Lancet.

[75]  E. Csernok,et al.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects , 1993, Clinical and experimental immunology.

[76]  G. Bodemar,et al.  Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. , 1993, Gut.

[77]  R. Gans,et al.  Clinical features and outcome in patients with glomerulonephritis and antineutrophil cytoplasmic autoantibodies. , 1993, Nephron.

[78]  W. Gross,et al.  Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). , 1993, Advances in experimental medicine and biology.

[79]  E. Bautz,et al.  Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. , 1993, Advances in experimental medicine and biology.

[80]  I. Caorsi,et al.  Antineutrophil-cytoplasmic-autoantibodies in poststreptococcal nephritis. , 1993, Advances in experimental medicine and biology.

[81]  G. Gaskin,et al.  Disease associations with anti-neutrophil cytoplasmic antibodies. , 1993, Advances in experimental medicine and biology.

[82]  A. Borne,et al.  Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity , 1992, Clinical and experimental immunology.

[83]  C. Kallenberg,et al.  Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. , 1992, The American journal of medicine.

[84]  M. Keogan,et al.  Activation of normal neutrophils by anti‐neutrophil cytoplasm antibodies , 1992, Clinical and experimental immunology.

[85]  J. Grünfeld,et al.  Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis , 1992, Clinical and experimental immunology.

[86]  C. Heesen,et al.  Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. , 1992, Arthritis and rheumatism.

[87]  K. Elkon,et al.  Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3. , 1992, Journal of immunology.

[88]  R. Terrell,et al.  Anti‐myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase , 1992, Clinical and Experimental Immunology.

[89]  J. Pearson,et al.  Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. , 1992, The American journal of pathology.

[90]  H. Kida,et al.  Two distinct types of crescentic glomerulonephritis. , 1992, Clinical nephrology.

[91]  E. Pettersson,et al.  Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. , 1992, Clinical nephrology.

[92]  M. Kamm,et al.  Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. , 1992, Gut.

[93]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[94]  R. Goldschmeding,et al.  Substrate and inhibitor studies on proteinase 3 , 1992, FEBS letters.

[95]  R. Falk,et al.  Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. , 1992, Kidney international.

[96]  A. Borne,et al.  Anti‐neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection , 1992, Clinical and experimental immunology.

[97]  K. Andrassy,et al.  Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. , 1992, Journal of the American Society of Nephrology : JASN.

[98]  R. Terrell,et al.  Antibodies Against Granule Proteins Activate Neutrophils In Vitro , 1991, Journal of leukocyte biology.

[99]  L. Revert,et al.  Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. , 1991, Clinical nephrology.

[100]  C. Kallenberg,et al.  Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. , 1991, The American journal of medicine.

[101]  P. Gueirard,et al.  Anti-myeloperoxidase antibodies: immunological characteristics and clinical associations. , 1991, Journal of autoimmunity.

[102]  J. Savige,et al.  Detection of anti‐myeloperoxidase and anti‐elastase antibodies in vasculitides and infections , 1991, Clinical and experimental immunology.

[103]  R. Wiesner,et al.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. , 1991, Gastroenterology.

[104]  G. Spickett,et al.  Aritineutrophil cytoplasmic antibodies, cystic fibrosis, and infection , 1991, The Lancet.

[105]  E. Ritz,et al.  Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. , 1991, Clinical nephrology.

[106]  P. Limburg,et al.  Predominance of IgGl and IgG4 subclasses of anti‐neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders , 1991, Clinical and experimental immunology.

[107]  A. Sjöholm,et al.  Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment , 1991, Journal of internal medicine.

[108]  R. Goldschmeding,et al.  Antimyeloperoxidase antibodies in the Churg-Strauss syndrome , 1991, Thorax.

[109]  E. Ritz,et al.  Clinical significance of the ANCA test for diagnosis of systemic necrotizing vasculitis. , 1991, Contributions to nephrology.

[110]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[111]  C. Kallenberg,et al.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.

[112]  T. Carey,et al.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.

[113]  T. The,et al.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.

[114]  A. Sjöholm,et al.  Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine‐induced lupus , 1990, Clinical and Experimental Immunology.

[115]  S. Targan,et al.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.

[116]  R. Falk,et al.  Antineutrophil cytoplasmic autoantibodies and associated diseases: a review. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[117]  R J Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[118]  J. Hoidal,et al.  Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. , 1990, Blood.

[119]  R. Gans,et al.  Different immunological specificities and disease associations of c-ANCA and p-ANCA. , 1990, The Netherlands journal of medicine.

[120]  C. Nathan,et al.  Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. , 1990, The Journal of clinical investigation.

[121]  D. Jayne,et al.  Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. , 1990, Kidney international.

[122]  R. Goldschmeding,et al.  Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. , 1990, Kidney international.

[123]  J. Lüdemann,et al.  Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme , 1990, The Journal of experimental medicine.

[124]  J. Velosa,et al.  Risk factors in idiopathic renal vasculitis and glomerulonephritis. , 1989, Kidney international.

[125]  M. Arnaout,et al.  Wegener9s granulomatosis autoantigen is a novel neutrophil serine proteinase [see comments] , 1989 .

[126]  C. Hack,et al.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. , 1989, The Journal of clinical investigation.

[127]  C. Kallenberg,et al.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.

[128]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. , 1989, The American journal of pathology.

[129]  M. Arnaout,et al.  Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. , 1989, Blood.

[130]  C. Nathan,et al.  Antibiotic proteins of human polymorphonuclear leukocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[131]  U. Specks,et al.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. , 1989, Annals of internal medicine.

[132]  S. Weiss Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[133]  J. Hoidal,et al.  Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. , 1988, The Journal of clinical investigation.

[134]  R. Goldschmeding,et al.  AUTOANTIBODIES AGAINST MYELOID LYSOSOMAL-ENZYMES - A NOVEL CLASS OF AUTOANTIBODIES ASSOCIATED WITH VASCULITIC SYNDROMES , 1988 .

[135]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.

[136]  W. Couser Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[137]  J. Neugarten,et al.  The existence of a protracted course in crescentic glomerulonephritis. , 1987, Kidney international.

[138]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[139]  B. Haynes,et al.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.

[140]  J. E. Moran,et al.  Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? , 1982, British medical journal.

[141]  H. Kreis,et al.  Rapidly progressive glomerulonephritis. A clinical and pathologic study. , 1978, The American journal of medicine.

[142]  K. Pryzwansky,et al.  Immunocytochemical localization of myeloperoxidase, lactoferrin, lysozyme and neutral proteases in human monocytes and neutrophilic granulocytes. , 1978, Journal of the Reticuloendothelial Society.

[143]  J. Schultz,et al.  Studies on the chlorinating activity of myeloperoxidase. , 1976, The Journal of biological chemistry.